EAGLE Crash Lands: AstraZeneca's Imfinzi/Tremelimumab Continues To Disappoint

The latest failure of the combination of AZ's PD-L1 inhibitor and its CLTA4 inhibitor is in advanced head and neck cancer. It follows recent failures of the MYSTIC and ARCTIC trials in lung cancer.

Eagle
AstraZeneca's EAGLE has not soared • Source: Shutterstock

AstraZeneca PLC's IO combiantion of Imfinzi and tremelimuab has failed in a Phase III study in head and neck cancer. Neither Imfinzi (durvalumab) monotherapy nor Imfinzi/tremelimumab combination treatment met the primary endpoint of overall survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that had progressed following platinum-based chemotherapy, in the EAGLE trial. Studies continue for in first-line head and neck cancer.

The company emphasized that the failed trial had studied the therapies in a "hard-to-treat" indication with a very poor prognosis....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer